COPD Market Analysis and Reports | Japan Conference Series

Market Analysis - COPD 2017

Summary of COPD 2017:

COPD 2017 conference is a three-day programme of presentations, panel discussions and interactive dialogue on leading the way in the COPD research development, which will be held during 29-31,May,2017 in Osaka, Japan.The event brings together Professors, researchers,key officials and delegates from almost 50 countries with interactive talks,sessions,workshops and symposiums in the current recent advancements in COPD strategies.

Importance & Scope:

Chronic obstructive pulmonary disease (COPD) is an important public health issue in many countries which is estimated to become the fifth cause of disability and the third cause of mortality in the world within 2020. This landmark study forms an additional foundation for the early history of smoking in order to identify abnormality and risk of progressive impairment on the pathway to symptomatic COPD

Why Osaka???

Osaka is a designated city in the Kansai region of Japan. It is the capital city of Osaka Prefecture and the largest component of the Keihanshin Metropolitan Area, the second largest metropolitan area in Japan and among the largest in the world with over 19 million inhabitants. OOsaka has started to garner more attention from foreigners with the increased popularity of cooking and dining in popular culture.

Major COPD Research Associations around Globe

Alpha-1 Foundation

American Association for Respiratory Care

American College of Chest Physicians

American College of Emergency Physicians

American College of Physicians

American Lung Association

Canadian Lung Association (CLA)

COPD Foundation

Major COPD Research Associations around Asia Pacific

COPD Patient Organization of Vietnam

COPD Patients Club Kyrgyzstan

COPD Club of Northern Thailand

Asian Pacific Society of Respirology

Chinese COPD Patient Education Organziation

Major Universities on COPD Research

Kumamoto University, Japan

Tokyo National Hospital,Japan

Kindai University,Japan

Okayama University,Japan

Medi7 Bentleigh, Australia

Macquarie University, Australia

Australian national university, Australia

Charles Darwin University Casoria Australia

Curtin University Bentley, Australia

Dar Al Uloom University, Saudi Arabia

Iqbal Chest Centre, Bangladesh

Imperial College London, United Kingdom

Linnaeus University, Sweden

University  Of California Los Angeles, United States

Columbia University Medical  Center, United States

Harvard University, United States

Global Market research on COPD

The global COPD market is estimated to currently be worth $11.3 billion, and is forecast to reach a value of $15.6 billion by 2019. The drugs driving this growth include once-daily LABA/LAMA fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium.

The opportunity in the U.S. and China asthma and COPD drugs market is slated to rise from a valuation of US$13.0 bn in 2015 to be worth US$18.7 bn by 2024. If these values hold true, the market is likely to expand at a modest CAGR of 4.1% therein.

North America leads the global market for asthma & COPD drugs and devices. North America was followed by Europe in terms of market capitalization. Asia Pacific is expected to be the fastest regional market for asthma and COPD owing to the increased incidence of asthma & other respiratory diseases in industrial regions.

The current asthma and COPD market is primarily driven by increasing patient population. It is also growing due to factors such as price erosion and expiry of patents of leading drug brands in the market. However, it is estimated that in the next five years, the global asthma and COPD drug market is expected to grow slowly and steadfast. The COPD segment was projected to be worth USD 10,593.2 million and is expected to reach USD 12,619.8 million in 2017.

In Europe, LABA / ICS combinations and LTA (Montelukast) drugs are more popular for asthma and COPD treatment.

TOP FACTORS IMPACTING GLOBAL COPD AND ASTHMA DEVICES MARKET

 

Top few companies in this global market:

AstraZeneca

GlaxoSmithKline

F. Hoffmann-La Roche

Novartis and Merck

Abbott

Amgen

Actavis

Boehringer Ingelheim

Cipla

Glenmark

Pfizer

Ranbaxy

Sunovion

Vectura

Global COPD & Asthma Devices Market, By Product

Inhalers

Nebulizers

Inhalers accounted for the major market and is expected to continue its dominance till 2020

Global COPD & Asthma Devices Market, By Geography

North America

Europe

Asia-Pacific

LAMEA

LAMEA region would exhibit the highest CAGR of 4.9% during 2017-2020

Bibiliography

https://industrytoday.co.uk/market-research-industry-today/global-asthma-and-copd-drug-market-market-research-size-growth-trend-analysis-

http://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=145

http://www.grandviewresearch.com/industry-analysis/asthma-and-copd-market

https://www.alliedmarketresearch.com/COPD-asthma-devices-market

http://www.gbiresearch.com/report-store/market-reports/therapy-analysis/chronic-obstructive-pulmonary-disease-(copd)-market-to-2019-highly-priced-new-combination-products-forecast-to-capture-signif